- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05825352
PMCF Study to Evaluate Performance and Safety of "Ocular Drops Based Upon Carmellose" Used to Relieve Dry Eye Symptoms
An Interventional, Non-comparative, Single-center Post Marketing Clinical Follow-up (PMCF) Study to Evaluate Performance and Safety of "Ocular Drops Based Upon Carmellose" Used to Relieve Dry Eye Symptoms
Dry eye disease (DED), also called keratoconjunctivitis sicca, is a multifactorial disease of the ocular surface characterized by loss of homeostasis of the tear film and accompanied by symptoms such as ocular discomfort and visual disturbance.
Tear Film & Ocular Surface Society Dry Eye Workshop (TFOS DEWS) II recommends individualized management of DED based on the relative contribution of aqueous deficient and evaporative pathophysiology (to the extent that this can be determined), as well as disease severity.
First-line for treating dry eye consists of over the counter (OTC) artificial tear drops, gels, ointments, or lubricants.
Carboxymethyl cellulose (CMC) is one of the most common viscous polymers used in artificial tears to achieve prolonged residence time on the ocular surface.
For these reasons, an interventional, non-comparative, single-center Post Marketing Clinical Follow-up (PMCF) study was planned to evaluate the performance and safety of "Ocular drops based upon carmellose" used as intended to relieve dry eye symptoms.
The objectives of the PMCF study are confirmation of the performance, collection of additional safety data regarding expected adverse events and detection of potential unexpected adverse events associated with use of "Ocular drops based upon carmellose" according the Instructions for Use (IFU).
Each subject, after signing the Informed Consent Form, will enter the screening and baseline phase (the 2 visits will coincide) during which baseline procedures will be completed.
At baseline visit (V0), one of the "Ocular drops based upon carmellose" products can be dispensed to the enrolled subject, depending on Investigator clinical evaluation and decision.
The patient will perform 2 on site visits: V0 and V2/EOS. To monitor the safety, 1 phone contact is planned (V1) to check for potential adverse events and concomitant medications intake.
The first administration and the intervals at which the treatment should be repeated, to be done as per Investigator judgment and according the IFU, depend on various factors regarding the physiology of the patients (e.g. type of eye-tear film, anatomy, age), their lifestyle (e.g. use of computer, wearing of contact lenses) and their eye-surgery history (if applicable).
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
CZ
-
Catanzaro, CZ, Italy, 88100
- Azienda Ospedaliera Policlinico Mater Domini - Università Magna Grecia di Catanzaro
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient Informed consent form (ICF) signed;
- Male and Female Aged ≥ 18 years at the time of the signature of the ICF;
- Patients with ocular symptoms such as burning, itching, and foreign body sensation due to environmental factors, contact lenses wearing and/or mild-severe dry eye;
- Willing not to use other eye drops during the entire treatment period.
Exclusion Criteria:
- Other - different - eyes clinical conditions (e.g. glaucoma);
- Known hypersensitivity or allergy to Investigational Product (IP) components;
- Suspected alcohol or drug abuse;
- Other clinically significant and uncontrolled pathologies that may interfere with study results (e.g. rheumatic diseases, diabetes);
- Participation in another investigational study;
- Inability to follow all study procedures, including attending all site visits, tests and examinations;
- Mental incapacity that precludes adequate understanding or cooperation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Eyedrops treatment arm
|
Ocular drops based upon carmellose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Schirmer Test I: to evaluate the lubricant and protecting performance of the "Ocular drops based upon carmellose" used as Intended in subjects with mild or severe dry eye syndrome, through the Schirmer I test
Time Frame: From baseline (V0 = Day 0) to 1 month (EOS/V2 = Day 30 ± 2)
|
From baseline (V0 = Day 0) to 1 month (EOS/V2 = Day 30 ± 2)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Tear Break-up Time (TBUT): to evaluate the performance of the "Ocular drops based upon carmellose" used as Intended to ensure relief from ophthalmic stress, through the TBUT test
Time Frame: From baseline (V0 = Day 0) to 1 month (EOS/V2 = Day 30 ± 2)
|
From baseline (V0 = Day 0) to 1 month (EOS/V2 = Day 30 ± 2)
|
|
Change in Ocular Surface Disease Index (OSDI): to evaluate the eye-discomfort relieving performance of the "Ocular drops based upon carmellose", through OSDI
Time Frame: From baseline (V0 = Day 0) to 1 month (EOS/V2 = Day 30 ± 2)
|
From baseline (V0 = Day 0) to 1 month (EOS/V2 = Day 30 ± 2)
|
|
To evaluate the safety and tolerability of the "Ocular drops based upon carmellose", through Visual Analogue Scale (VAS) - evaluation of symptoms related to dry eye disease (burning, fatigue, discomfort, redness)
Time Frame: End of study visit (EOS/V2 = Day 30 ± 2)
|
Visual Analogue Scale: Minimum value = 0; Maximum value = 10; Higher scores mean a better outcome. |
End of study visit (EOS/V2 = Day 30 ± 2)
|
To evaluate the patient satisfaction through a Rensis Likert 5 points patient satisfaction scale
Time Frame: End of study visit (EOS/V2 = Day 30 ± 2)
|
Rensis Likert 5 points patient satisfaction scale: Minimum value: Very dissatisfied Maximum value: Very satisfied High score means better outcome. |
End of study visit (EOS/V2 = Day 30 ± 2)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- COC-R4-CMC
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Eye
-
Gordon Schanzlin New VisionCompletedDry Eye | Dry Eye Disease | Evaporative Dry Eye | Kerato Conjunctivitis Sicca | Evaporative Dry Eye Disease | Dry Eye, EvaporativeUnited States
-
Alcon ResearchCompletedVisual Performance | Dry Eye Symptoms
-
Alcon ResearchCompletedModerate to Severe Dry Eye
-
Singapore National Eye CentreCompleted
-
AllerganCompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
Kao (Taiwan) CorporationChang Gung Memorial HospitalCompletedEye Fatigue | Dry Eye SymptomTaiwan
-
Bausch & Lomb IncorporatedCompletedDry Eye Disease (DED)United States
-
Centre for Contact Lens ResearchCoopervision, Inc.CompletedContact Lens Related Dry EyeCanada
-
Singapore National Eye CentreCompleted
-
Senju Pharmaceutical Co., Ltd.CompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
Clinical Trials on Carmellose eye drops
-
Hai Yen Eye CareBrien Holden Vision InstituteCompleted
-
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical...Recruiting
-
Medical University of ViennaCompleted
-
Alcon ResearchCompleted
-
AllerganCompletedDry Eye SyndromesUnited States
-
Alcon ResearchCompletedDry EyeUnited States
-
Allgenesis Biotherapeutics Inc.CompletedPterygiumAustralia
-
Fovea Pharmaceuticals SACompletedDiabetic Macular EdemaUnited States, Australia, Belgium, Czech Republic, France, Germany, Israel, Italy, Poland, Spain
-
Alcon ResearchCompleted